File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Study on hybridized yeast-based HIV vaccine

TitleStudy on hybridized yeast-based HIV vaccine
Authors
KeywordsGene Engineering
Hiv
Vaccine
Yeast Hybridization
Issue Date2006
Citation
Chinese Journal Of Microbiology And Immunology, 2006, v. 26 n. 11, p. 1033-1037 How to Cite?
AbstractObjective: To perform pre-clinical study on a yeast-based HIV vaccine. Methods: Plasmids expressing Gag and IL-2 was respectively constructed and then transformed into yeast; yeast hybridization was performed to obtain yeast hybrid concurrently expressing Gag and IL-2; culture of yeast hybrid in large scale was performed. The final vaccine product was obtained through series of process including inactivation, lyophilization and filling. The efficacy and safety of the vaccine was analyzed in mouse and macaque models. Results: Expression of Gag and IL-2 in yeast hybrid is stable. Upon subcutaneous injection, HIV vaccine derived from the yeast hybrid could elicit strong Gag-specific cellular immune responses in mice and in macaque models, respectively. In addition, vaccine could also elicit strong protection from tumor challenge in mice. Study on safety indicated that, except for slight tenderness and swelling at the site of injection, there was no obvious acute as well as chronic toxicity. Conclusion: Yeast hybrid can be used as a vehicle for vaccine; yeast hybrid-based vaccine is capable of inducing strong antigen-specific cellular immune responses. Our studies imply that yeast hybrid is a promising vector and delivery system for the development of novel therapeutic vaccine candidates against infections and tumors.
Persistent Identifierhttp://hdl.handle.net/10722/157473
ISSN
2015 SCImago Journal Rankings: 0.108
References

 

DC FieldValueLanguage
dc.contributor.authorZhang, SEen_US
dc.contributor.authorXiong, Qen_US
dc.contributor.authorTang, HBen_US
dc.contributor.authorLiu, JYen_US
dc.contributor.authorWu, YYen_US
dc.contributor.authorWu, DPen_US
dc.contributor.authorTian, WZen_US
dc.contributor.authorLu, JHen_US
dc.contributor.authorZheng, BJen_US
dc.contributor.authorSun, Jen_US
dc.date.accessioned2012-08-08T08:50:16Z-
dc.date.available2012-08-08T08:50:16Z-
dc.date.issued2006en_US
dc.identifier.citationChinese Journal Of Microbiology And Immunology, 2006, v. 26 n. 11, p. 1033-1037en_US
dc.identifier.issn0254-5101en_US
dc.identifier.urihttp://hdl.handle.net/10722/157473-
dc.description.abstractObjective: To perform pre-clinical study on a yeast-based HIV vaccine. Methods: Plasmids expressing Gag and IL-2 was respectively constructed and then transformed into yeast; yeast hybridization was performed to obtain yeast hybrid concurrently expressing Gag and IL-2; culture of yeast hybrid in large scale was performed. The final vaccine product was obtained through series of process including inactivation, lyophilization and filling. The efficacy and safety of the vaccine was analyzed in mouse and macaque models. Results: Expression of Gag and IL-2 in yeast hybrid is stable. Upon subcutaneous injection, HIV vaccine derived from the yeast hybrid could elicit strong Gag-specific cellular immune responses in mice and in macaque models, respectively. In addition, vaccine could also elicit strong protection from tumor challenge in mice. Study on safety indicated that, except for slight tenderness and swelling at the site of injection, there was no obvious acute as well as chronic toxicity. Conclusion: Yeast hybrid can be used as a vehicle for vaccine; yeast hybrid-based vaccine is capable of inducing strong antigen-specific cellular immune responses. Our studies imply that yeast hybrid is a promising vector and delivery system for the development of novel therapeutic vaccine candidates against infections and tumors.en_US
dc.languageengen_US
dc.relation.ispartofChinese Journal of Microbiology and Immunologyen_US
dc.subjectGene Engineeringen_US
dc.subjectHiven_US
dc.subjectVaccineen_US
dc.subjectYeast Hybridizationen_US
dc.titleStudy on hybridized yeast-based HIV vaccineen_US
dc.typeArticleen_US
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_US
dc.identifier.authorityZheng, BJ=rp00353en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-33847034839en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33847034839&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume26en_US
dc.identifier.issue11en_US
dc.identifier.spage1033en_US
dc.identifier.epage1037en_US
dc.identifier.scopusauthoridZhang, SE=15849864200en_US
dc.identifier.scopusauthoridXiong, Q=55222654600en_US
dc.identifier.scopusauthoridTang, HB=15849485200en_US
dc.identifier.scopusauthoridLiu, JY=26651214700en_US
dc.identifier.scopusauthoridWu, YY=15849886300en_US
dc.identifier.scopusauthoridWu, DP=15849818600en_US
dc.identifier.scopusauthoridTian, WZ=55137435500en_US
dc.identifier.scopusauthoridLu, JH=8079348400en_US
dc.identifier.scopusauthoridZheng, BJ=7201780588en_US
dc.identifier.scopusauthoridSun, J=37071291400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats